SPD503 (3 mg)

DRUG2 trials

Sponsors

Shire

Conditions

Attention Deficit Disorder With Hyperactivity

Phase 3

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

CompletedNCT00150618

ShireAttention Deficit Disorder With Hyperactivity

Start: 2004-03-30End: 2004-10-07Updated: 2021-06-10

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

CompletedNCT00152009

ShireAttention Deficit Disorder With Hyperactivity

Start: 2003-01-29End: 2003-08-23Updated: 2021-06-10